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CObjective: To compare the total direct health-care costs of patients
treated with tiotropium and ipratropium. Methods: We conducted a
cohort study of health-care costs in British Columbia, Canada, by
comparing new patients on tiotropium with new patients on iprat-
ropium. Direct health-care costs for study patients were measured
in the first 2 years after initiating inhaled anticholinergic treatment.
Differences in direct health-care costs between tiotropium and ipra-
tropium patients were estimated by using quantile regression. We
analyzed cost differences in the 10th percentile, median, and 90th
percentile of patients by cost. High-dimensional propensity score
analysis was used as a method of adjustment for potential con-
founding factors. Results: The study population had 3,140 tiotro- O
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doi:10.1016/j.jval.2011.10.014ium patients and 26,182 ipratropium patients. Higher health sys-
em costs in patients who started on tiotropium instead of
pratropium were observed in patients in the median and 10th per-
entile. The magnitude of these increases was comparable to the
rice difference between the two drugs. Health system costs in the
0th percentile were not significantly different between tiotropium
nd ipratropium patients. Conclusions: The results of this study did
ot support the preferential use of tiotropium over ipratropium as a
asis for savings in direct health-care costs.
eywords: COPD, health care, respiratory disease, tiotropium, utilization.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Chronic obstructive pulmonary disease (COPD) is a major and
growing cause of mortality and morbidity worldwide [1–3]. In
North America, it is estimated that 19% of the population is living
with the disease [4]. In Canada, in 2003, total direct health-care
costs of COPDwere estimated to beCan $1997 per patient [5]. In the
United States, total direct health-care costs were estimated at US
$4120 per patient [6]. More than half of all direct health-care costs
in North American patients were inpatient hospital costs [5,6]. It
has been argued that the burden of COPD could be curtailed by
more extensive use of smoking cessation and pulmonary rehabil-
itation interventions and greater use of inhaled medications [5].
Inhaled anticholinergics (IACs) are among the most common
medications used to treat COPD. The two IACs usedmost often are
ipratropium bromide (Atrovent®) and tiotropium bromide
(Spiriva®). Ipratropium is available as an aerosol inhaler and as a
solution used with a nebulizer. Tiotropium is indicated for long-
term maintenance treatment of bronchospasm associated with
COPD, including chronic bronchitis and emphysema. It is a longer
acting anticholinergic than ipratropium. Tiotropium is usually
taken once a day in the form of capsules that are inserted into a
handheld device and released as a powder when inhaled. In this
regard, once-a-day tiotropium provides a convenience advantage
* Address correspondence to: Colin R. Dormuth, Department of A
Columbia, 1110 Government Street, Suite 210, Victoria, BC, Canad
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1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.over ipratropium, which, because it has a shorter duration of ac-
tion, is usually taken in multiple inhalations throughout the day.
Tiotropium is considerably more expensive than ipratropium
(CAN $2.49 per day prescription in 2009 compared with Can $1.30
for ipratropium). The cost difference and therapeutic substitut-
ability of the drugs suggest that economic comparisons of the two
could be useful to health-care insurers. If tiotropium results in
better health outcomes than does ipratropium in otherwise simi-
lar patients, either because it is therapeutically superior or be-
cause convenience improves persistence on treatment, then bet-
ter outcomes should translate to lower direct health-care
expenditures in those patients so long as any reduction inmedical
costs exceed the additional cost of the drug.
In terms of existing evidence, meta-analyses of randomized
trials havemixed results. Some suggested that tiotropium reduces
COPD-related hospitalizations or exacerbation-related hospital-
izations compared with placebo [7–9]. One of these meta-analyses
also found anonsignificant reduction in COPD-related hospitaliza-
tions with tiotropium in comparison with salmeterol [7]. One pla-
cebo-controlled trial measured all-cause hospitalizations and re-
ported that tiotropium reduced all-cause hospitalizations [10].
Not all studies were unanimous. One trial that examined all-
cause hospitalization did not find a significant difference [11], al-
though it did report a significant improvement in hospitalizations
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270 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 6 9 – 2 7 6due to COPD exacerbation in tiotropium patients. And one of two
cohort studies evaluating COPD hospitalizations found a de-
creased risk of COPD referrals and hospitalizations with tiotro-
pium as compared with ipratropium and salbutamol [12], while
nother found an increased risk of hospitalizations associated
ith tiotropiumuse as comparedwith nonuse [13]. In a time series
nalysis in British Columbia, there was a modest but statistically
ignificant increase in emergency hospital admissions for COPD
hat coincided with the introduction of public drug coverage for
iotropium [14].
We conducted a population-based cohort study of direct
ealth-care cost in British Columbia, Canada, in patients with
OPD who were newly initiated on tiotropium or ipratropium.
e compared the direct health-care system costs in both
roups over the first 2 years of treatment and adjusted for po-
ential confounding factors. The lack of consistency of results
cross available studies suggested that cost increases or decreases
ttributable to tiotropiumwere both plausible hypotheses. There-
ore, we expected a priori that direct health-care costs in tiotro-
iumpatients could be either reduced or increased relative to ipra-
ropium patients.
Methods
We designed a prospective cohort study by using data collected by
the British Columbia Ministry of Health (MoH) between January 1,
2002, and December 31, 2008. The primary analysis assessed the
total direct health-care costs from the perspective of the MoH.
Secondary analyses examined hospital, physician services, and
prescription drug costs separately. In British Columbia, all hospital
costs and medically necessary physician visits were fully covered
by the government. In addition, the government subsidized ap-
proximately half of all prescription drug costs.
All prescriptions that were dispensed at community pharma-
cies were recorded in a centralized database known as PharmaNet
and were linkable using unique patient identifiers with a central-
ized Discharge Abstract Database for hospitalizations and a cen-
tralized Medical Services Plan database for physician visits. These
databases included diagnostic codes (International Classification of
Diseases, Ninth Revision, for physician visits and International Statis-
tical Classification of Diseases, Tenth Version, for hospitalizations),
procedure codes, service dates, admission dates, and death dates.
We assumed that the completeness and misclassification of diag-
nostic coding was comparable to other administrative databases.
Complete data were unavailable for federally insured patients
such as Aboriginals, Royal CanadianMounted Police, armed forces
personnel, and prisoners. These groups comprised about 4% of the
population.
Study population
The source population for the analysis included the person-time
of all British Columbia residents who were at least 50 years of age
between January 1, 2003, and December 31, 2006, and who were
not federally insured for their medical coverage. The study popu-
lation was drawn from the source population by extracting all
prescriptions for tiotropium and ipratropium in the PharmaNet
database that were dispensed between January 1, 2002, and De-
cember 31, 2006. These date ranges were chosen to maximize co-
hort enrolmentwhile ensuring that study participants had at least
365 days of historical data preceding their first IAC prescription,
and, similarly, up to 720 days of health-care utilization data avail-
able after initiating treatment. The study population included new
users of ipratropium or tiotropium where new use was defined as
no previous dispensing for an IAC in the previous year.We defined
a study index date for each patient equal to the date of his or her
first IAC dispensing. Patients were excluded from the analysis ifthey were younger than 50 years of age on their index date, were
not enrolled in the Medical Service Plan for at least 1 year before-
hand, if information on age or sex wasmissing, or if they were in a
palliative care unit or long-term care facility prior to the index
date.
Outcomes
Direct health-care costs were measured for each patient for up to
720 days after initiation on tiotropium or ipratropium. Patients
were censored earlier than 720 days at the earliest occurrence of
one of the following: switching between ipratropium and tiotro-
pium, de-enrolment from the Medical Services Plan, or death. The
primary outcome was total direct health-care costs, which we de-
fined as the total sum of physician fee-for-service visit costs, hos-
pitalization costs, and prescription drug costs. Each of the three
component costs of total cost were analyzed separately as second-
ary outcomes. Each physician visit recorded in the Medical Ser-
vices Plan database included the fee amount paid to the physician.
For prescriptions, we used the ingredient cost amount and dis-
pensing fee amounts charged by the pharmacy (regardless of
payer). The actual cost of hospital stays is not calculated in Can-
ada. Instead, hospitals receive global funding from their provincial
MoH, and discharge records include a resource intensity weight
(RIW) that can be used to estimate cost. RIWs are calculated by the
Canadian Institute for Health Information. The RIW is an estimate
of the relative amount of resources used by a patient during a
hospital stay. Detailed information on RIW methodology can be
obtained from www.cihi.ca. The British Columbia MoH estimates
a dollar for an RIW by considering a number of factors including
the total number of RIWs that a hospital accumulated and the
amount of funding it received. As of June 22, 2009, the MoH in
British Columbia estimated the cost of 1 RIW in the fiscal year
2008-2009 to be CAN $5012. For years prior to 2008/09, we used an
adjusted RIW that when multiplied by CAN $5012 yielded the cost
for the admission in 2008 dollars.
Statistical analysis
We conducted a modified high-dimensional propensity score
(hdPS) analysis [15]. In the first step of the analysis, we identified
five data dimensions: International Classification of Diseases, Ninth
Revision, diagnoses in hospital records (first three digits), medical
procedures in hospital records, International Classification of Dis-
eases, Ninth Revision, diagnoses in physician visit records (first
three digits), fee billing items in physician visit records, and Amer-
ican Hospital Formulary Service medication code in prescription
drug records (fourth tier eight digits). Next, we identified poten-
tial covariates in our study population by sorting codes within
each of the five data dimensions according to their prevalence.
Prevalence was measured as the proportion of patients having a
specific code at least once during a 1-year baseline period. Because
the prevalence of a binary factor is symmetrical around 0.5, we
subtracted all prevalence estimates larger than 0.5 from 1.0. Codes
were excluded from further analysis if less than 0.5% of patients or
more than 99.5% of patients were identified as having it. We then
selected up to 200 of the remaining codes from each data dimen-
sion for further analysis as potential covariates. From the up to 200
codes chosen from each data dimension we measured how fre-
quently each code was recorded for each patient during the base-
line period. We then divided each code into four binary variables
for whether the code occurred: 1 time, the median number of
times, the 75th percentile number of times, or the 90th percentile
number of times. The 90th percentile was a modification to the
original hdPS algorithm. A code that appeared above the 90th per-
centile number of times had a “true” value for all four recurrence
variables. If any of the valueswere equal, the variable representing
the lower cut point was excluded.
t271V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 6 9 – 2 7 6In each data dimension we estimated the amount of potential
confounding that each covariate could produce in amultiplicative
model according to the following formula:
BiasMult
PC1(RRCD 1) 1
PC0(RRCD 1) 1
if RRCD 1
PC1[1 ⁄ (RRCD) 1] 1
PC0[1 ⁄ (RRCD) 1] 1
otherwise
where PC1 and PC0 were the prevalence of the covariate (C) in the
iotropium (1) and ipratropium (0) patients, respectively, and RRCD
was the association between the potential confounder and a bi-
nary outcome indicator for cost (D). Conversion of the continuous
cost variable to a binary indicator was done as a further modifica-
tion to the hdPS algorithm and was done because the multiplica-
tive bias formula was applicable to a binary outcome and a binary
covariate. In performing this conversion, patients with health-
care costs below the median cost were assigned a cost indicator
value of 0. Patients at or above themedianwere assigned a value of
1. In a sensitivity analysis, propensity scores were re-estimated by
using two other cutoff values for converting the continuous cost
variable to a dichotomous one. Applying a cutoff as low as the 25th
percentile or as high as the 75th percentile did not appreciably
change the propensity score distribution.
The covariates from all of the data dimensions were sorted
together in descending order of their estimated multiplicative
bias, and the top 500were selected to be included in the propensity
score analysis. Logistic regression was used to estimate the pre-
dicted probability of exposure to tiotropium conditional on all in-
cluded covariates (i.e., propensity score). In addition to the 500
empirically selected covariates, we included an indicator variable
for patient sex, categorical variables for age (in 5-year groupings),
calendar year of treatment initiation, and categorical variables for
patient Romano comorbidity score [16].
Average health-care system costs can be easily skewed by ex-
ceptionally ill patients to a degree that the average is not repre-
sentative of any real patient. Furthermore, sicker patients are
sometimes disproportionately channeled to newer treatments. To
provide a more representative measure of cost, and to avoid bias-
ing the analysis against the newer study drug (tiotropium), we
estimated median costs instead of mean costs by using quantile
regression. Quantile regression is similar to optimization-type re-
gression on a datamean, but rather than finding the samplemean
by minimizing the sum of squared residuals, as would be done in
a conventional linear regression, the sample median is estimated
by minimizing the sum of absolute residuals [17]. We used the
Quantreg procedure in SAS (SAS Institute Inc., Cary, NC, USA) to
perform the analysis on each outcome. We repeated the analysis
on the 90th percentile of patients by cost (themost costly patients)
and the 10th percentile of patients by cost (the least costly pa-
tients). The quantile regressionmodels included a binary indicator
variable for treatment assignment (1 for tiotropium and 0 for
ipratropium) and nine indicator variables for decile of propensity
score.
Results
Between January 1, 2003, and December 31, 2006, 4,685 patients
were started on tiotropium and 47,208 patients were started on
ipratropium. Of these patients, 1,545 tiotropium patients and
21,026 ipratropium patients were excluded because they had ei-
ther filled a prescription under British Columbia’s provincial pal-
liative care drug plan or long-term care drug plan, were of un-
known age or sex, or were younger than 50 years of age at the time
of their initial prescription. The final study population had 3,140
tiotropium patients and 26,182 ipratropium patients. Ninety-eight
percent of patients in both treatment groups remained in thestudy for the entire 720-day follow-up period. Of patients who
exited the study early, themedian follow-up timewas 495 days for
tiotropium patients and 400 days for ipratropium patients.
Baseline characteristics of the study population are shown in
Table 1. The average age of study participants was 68 years, and
53% of the patients were women. Ipratropium patients were more
likely to be from lower income brackets. In terms of baseline
health status, there were few notable differences between the
treatment groups. The ipratropium group had more patients with
a Romano score of zero (tiotropium: 26%; ipratropium: 40%), which
indicates that these patients had no major diagnosed morbidities
in the year prior to initial treatment. The tiotropium group had
higher percentages of patients with asthma and COPD diagnoses
but lower percentages of patients with diagnoses classified as
other airway disease or respiratory infection. The characteristics
of a propensity-score–matched subset of the study population
were balanced across treatment groups (Table 2) and were used to
provide data on comparability of the two groups conditional on
the propensity score.
We examined the 10th percentile, median, and 90th percentile
of patients by total direct health-care cost (Table 3). In our propen-
sity-score–adjusted study population, there was no evidence that
patients started on tiotropium incurred lower health-care costs
than did patients started on ipratropium in the first 2 years after
initiating treatment. There was a clear total cost disadvantage of
tiotropium over ipratropium across all eight quarters for both the
median and 10th percentile, with quarterly cost differences typi-
cally occurring in the Can $50 to Can $100 range per patient. In the
90th percentile of patients, the most expensive patients in terms
of health-care costs, the estimated differences in cost were less
apparent. Although point estimates in six of eight quarters fa-
vored ipratropium, differences were not statistically significant in
seven of eight quarters, and no drug clearly appeared to be supe-
rior to the other. Median differences in total cost by quarter are
plotted in Figure 1. In addition to median total direct costs for
tiotropiumpatients exceeding those for ipratropiumpatients in all
quarters, there was a significant trend in increased median cost
differences over time (b  6.5 per quarter; P  0.01).
Median cost differences for prescription drugs and physician
visits are shown in Table 4. With the exception of the first 90 days
after treatment initiation, physician visit costs did not differ sig-
nificantly between study arms. Median prescription drug costs,
which included the cost of the study drugs, were typically Can $75
to Can $95 greater in all quarters of follow-up in patients who
initiated treatment with tiotropium. Median cost differences for
hospitalizations were zero because a majority of patients in the
first 2 years of follow-up were not admitted to hospital. Differ-
ences in average hospital costs were not statistically significant in
any quarter. Chronologically, those average costs per patient per
quarter were as follows (95% confidence intervals in parentheses):
39 (249 to 170), 85 (345 to 176), 41 (195 to 114), 67 (248
to 115), 21 (181 to 140), 78 (103 to 258), 69 (96 to 235), and
121 (296 to 53).
Discussion
Varying results from previous studies on the benefits of tiotro-
pium prevented us from having a strong a priori expectation for
the results of this analysis. It was plausible that direct health-
care costs would possibly be lower for patients initially treated
with tiotropium, both because some studies found reductions in
hospitalizations with tiotropium and also because a conve-
nience advantage over ipratropium could have improved treat-
ment persistence. What we observed were statistically signifi-
cantly higher costs in patients who started on tiotropium
instead of ipratropium in the median and 10th quartile of pa-
tients by cost. The magnitude of these increases was compara-
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Characteristic Ipratropium Tiotropium
n % n %
Patients 26,182 3,140
Age (y)
50–54 2,727 10 229 7
55–59 3,561 14 387 12
60–64 3,856 15 500 16
65–69 4,087 16 551 18
70–74 4,365 17 529 17
75–79 3,862 15 482 15
80–84 2,433 9 301 10
85 1,291 5 161 5
Sex
Women 13,925 53 1,593 51
Men 12,257 47 1,547 49
Income band* (Can $)
0–25,000 7,359 28 629 20
25,001–50,000 6,368 24 907 29
50,001–100,000 4,039 15 872 28
100,000  892 3 228 7
Non–income-based plan 2,900 11 55 2
Unregistered 4,624 18 449 14
Romano score†
0 10,365 40 806 26
1–2 13,227 51 1,959 62
3–4 2,244 9 340 11
5 346 1 35 1
Diagnoses between in previous 365 d
Asthma (ICD493)‡ 4,762 18 994 32
COPD (ICD490-492, 494-496) 7,578 29 1,579 50
Other airway disease (ICD466, 480-486, 7700) 6,959 27 795 25
Respiratory infection (ICD460-465) 5,218 20 597 19
Hospital discharges in previous 365 days
1 5,974 23 664 21
2 2,425 9 216 7
2 1,655 6 109 3
Median number of prescriptions in previous 365 d 19 20
Hospital costs (Can $) 10,990 5,887
Prescription costs (Can $) 1,509 1,794
Physician visit costs (Can $) 1,563 1,424
2003 Qtr 1 1,826 7 70 2
2003 Qtr 2 1,633 6 207 7
2003 Qtr 3 1,241 5 142 5
2003 Qtr 4 1,927 7 197 6
2004 Qtr 1 1,880 7 156 5
2004 Qtr 2 1,495 6 180 6
2004 Qtr 3 1,216 5 144 5
Calendar year of index dispensing
2004 Qtr 4 1,772 7 219 7
2005 Qtr 1 1,996 8 205 7
2005 Qtr 2 1,645 6 218 7
2005 Qtr 3 1,323 5 217 7
2005 Qtr 4 1,654 6 226 7
2006 Qtr 1 1,999 8 233 7
2006 Qtr 2 1,669 6 264 8
2006 Qtr 3 1,319 5 205 7
2006 Qtr 4 1,587 6 257 8
COPD, chronic obstructive pulmonary disease.
* Author-defined groupings of Fair PharmaCare income-based drug plans. These groupings combine Fair PharmaCare Regular Assistance
(nonseniors) and Enhanced Assistance (seniors) plans.
† The Romano score is a diagnosis-based score derived from the Charlson index of 19 conditions; each has a weight from 1 to 6. The score for
each patient is equal to the sum of the weights.
‡ The International Classification of Diseases, Ninth Revision (ICD-9).
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Characteristic Ipratropium Tiotropium
n % n %
Patients 3,076 3,076
Age (y)
50–54 253 8 229 7
55–59 350 11 377 12
60–64 460 15 489 16
65–69 576 19 535 17
70–74 489 16 520 17
75–79 465 15 468 15
80–84 309 10 298 10
85 174 6 160 5
Sex
Women 1,585 52 1,562 51
Men 1,491 48 1,514 49
Income band* (Can $)
0–25,000 625 20 624 20
25,001–50,000 877 29 892 29
50,001–100,000 851 28 842 27
100,000 215 7 216 7
Non–income-based plan 65 2 55 2
Unregistered 443 14 447 15
Romano score†
0 768 25 803 26
1–2 1,950 63 1,910 62
3–4 322 10 330 11
5 36 1 33 1
Diagnoses between in previous 365 d
Asthma (ICD493)‡ 982 32 957 31
COPD (ICD490-492, 494-496) 1,447 47 1,528 50
Other airway disease (ICD466, 480-486, 7700) 821 27 775 25
Respiratory infection (ICD460-465) 606 20 583 19
Hospital discharges in previous 365 d
1 647 21 649 21
2 229 7 214 7
2 117 4 108 4
Median number of prescriptions in previous 365 d 21 20
Hospital costs (Can $) 6,138 5,963
Prescription costs (Can $) 1,681 1,659
Physician visit costs (Can $) 1,436 1,420
2003 Qtr 1 136 4 70 2
2003 Qtr 2 137 4 205 7
2003 Qtr 3 118 4 140 5
2003 Qtr 4 181 6 195 6
2004 Qtr 1 201 7 152 5
2004 Qtr 2 166 5 179 6
2004 Qtr 3 141 5 144 5
Calendar year of index dispensing
2004 Qtr 4 208 7 212 7
2005 Qtr 1 244 8 195 6
2005 Qtr 2 206 7 215 7
2005 Qtr 3 174 6 216 7
2005 Qtr 4 233 8 221 7
2006 Qtr 1 280 9 229 7
2006 Qtr 2 258 8 259 8
2006 Qtr 3 167 5 197 6
2006 Qtr 4 226 7 247 8
COPD, chronic obstructive pulmonary disease.
* Author-defined groupings of Fair PharmaCare income-based drug plans. These groupings combine Fair PharmaCare Regular Assistance
(nonseniors) and Enhanced Assistance (seniors) plans.
† The Romano score is a diagnosis-based score derived from the Charlson index of 19 conditions; each has a weight from 1 to 6. The score for
each patient is equal to the sum of the weights.
‡ The International Classification of Diseases, Ninth Revision (ICD-9).
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observe any significant differences when we analyzed the phy-
sician visit and hospitalization costs separately. These results
suggest that tiotropium patients were more costly at least in
part due to the higher cost of their medication. Tiotropium also
did not appear to provide a health-care cost advantage in the
most costly patients (at the 90th percentile). Significantly higher
costs in tiotropium patients in the second and sixth quarters of
follow-up were not sufficiently compelling to conclude, in our
study population, that ipratropium was advantageous in higher
cost patients.
Although we controlled for calendar year of initiation on
treatment, we observed a significant trend over time toward an
Table 3 – Total direct costs* per patient over 720 days for 3
Quantile
( cost difference fav
1 2 3
10th Quantile
(Lowest Cost Patients)
Tiotropium 114 96 94
Ipratropium 76 44 41
Difference† 38 52 53
L95% C.I. 21 34 33
U95% C.I. 55 70 73
Median
(Typical Cost Patients)
Tiotropium 557 563 549
Ipratropium 512 487 472
Difference† 45 76 77
L95% C.I. 12 49 49
U95% C.I. 78 103 105
90th Quantile
(Highest Cost Patients)
Tiotropium 1880 2170 1787
Ipratropium 2136 1976 1820
Difference† 255 194 33
L95% C.I. 535 2 198
U95% C.I. 25 385 131
* Costs are indicated in Canadian dollars per patient (1 dollar CAD equ
include hospital costs, physician visit costs and prescription drug c
† L95% C.I. and U95% C.I. denote the lower 95% and upper 95% confid
Fig. 1 – Difference in median direct health care cost per
patient treated with tiotropium or ipratropium.increase in median cost differences between tiotropium and
ipratropium patients. The reasons for this result are not imme-
diately obvious. At 28%, overall spending on health care in Brit-
ish Columbia increased rapidly over the study period [18]. It is
reasonable that annual global increases of approximately 5% in
health-care funding would be applied equally to patients in
both treatment groups, but if one group was more expensive
than the other, an identical multiplicative increase of 5% per
year on average would translate into larger absolute differences
over time. Another possible reason for the trend could be dif-
ferences in treatment persistence on the two drugs in some
patients. Tiotropium has a convenience advantage and a drug
cost disadvantage compared with ipratropium. The former
could improve drug persistence in some patients and therefore
increase drug costs. The latter could reduce drug persistence in
some patients and possibly increase health-care costs because
of suboptimal disease control. Yet another possible explanation
can be derived from previous studies that found an increase in
hospitalizations in tiotropium patients [13,14]. If tiotropium ac-
tually increases the risk of hospitalization compared with ipra-
tropium, then it is reasonable to expect that such added risk
would also increase health-care costs. This analysis, however,
cannot be taken as direct evidence of any of the above effects.
Our study had some limitations. With any observational
study there can be no guarantee that the analysis is immune to
bias from confounding factors. The hdPS method employed a
rigorous and systematic approach to adjustment for confound-
ing. Data on a matched subset of patients demonstrated that
tiotropium and ipratropium patients were comparable on ob-
served characteristics conditional on their propensity score, in-
cluding cost in the year prior to drug initiation (Table 2). This
feature of the analysis provided some assurance that the hdPS
method provided adjustment for confounding, at least for mea-
tiotropium and 28,162 ipratropium patients.
Quarter
ipratropium/ cost difference favors tiotropium)
4 5 6 7 8
102 121 105 102 114
46 61 49 45 51
56 60 55 57 62
34 39 34 34 43
78 82 76 80 82
576 619 608 629 638
495 513 514 533 540
81 106 94 96 98
50 77 66 65 63
112 135 123 127 134
1951 1935 2216 2211 2251
1906 1930 1974 2123 2168
45 5 242 88 83
175 220 61 174 147
265 230 545 350 313
pproximately 1 dollar USD). Components included in total direct cost
interval for the difference between tiotropium and Ipratoprium.,140
ors
als a
osts.surable factors. Unmeasured confounding could still have been
ence
275V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 6 9 – 2 7 6a factor in the analysis. For example, tiotropiumwas a new drug
during the study period and it is possible that higher risk pa-
tients were preferentially channeled toward tiotropium rather
than ipratropium. Our use of administrative claims data for di-
agnoses, medical procedures, and drug use may not have cap-
tured all relevant information on health status, and to the ex-
tent that important data were lacking in the analysis, our
results could have been biased. Different results may also have
been obtained if other nonsystem costs were included. Finally,
our analysis provided useful information on the relative costs of
two active treatments, but it did not offer any information on
whether treatment with tiotropium or ipratropium is preferable
to treatment with other inhaled medications, or no IAC what-
soever.
The cost structure of health-care services in British Columbia is
also somewhat unique, and the absolute cost differences we ob-
served are not necessarily generalizable to other jurisdictions.
This is less of a concern for hospital costs and physician costs
where we did not find evidence of a difference. Jurisdictional
uniqueness is most relevant to the cost difference between iprat-
ropium and tiotropium in that the advantage of ipratropium
would be comparatively greater in jurisdictions where the price
difference with tiotropium was larger, and comparatively less
where the price difference was smaller.
This study did not provide support for preferential use of
tiotropium over ipratropium with regard to direct health-care
costs. Health plans that pay for tiotropium in anticipation of cost
savings on hospital and physician servicesmaywish to reconsider
their tiotropium policies with respect to patients with COPD and
determine whether coverage remains warranted on the basis of
added convenience or other real or perceived advantages of the
drug.
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